Pirtobrutinib Drug Asset Due Diligence Report 2026

This Pirtobrutinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pirtobrutinib can convert its Small molecule drug profile and BTK C481S biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pirtobrutinib (query alias: pirtobrutinib)
Modality / target	Small molecule drug; BTK C481S; BTK C481S inhibitors
Highest global status	Approved
Originator	Redx Pharma Plc
Active developers	Eli Lilly Suzhou Pharmaceutical Co. Ltd., Eli Lilly & Co., Loxo Oncology, Inc.

The MCP disease footprint includes Refractory Small Lymphocytic Lymphoma, Chronic lymphocytic leukaemia refractory, Recurrent Chronic Lymphoid Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07624799	Phase 2	Not yet recruiting	82	Peripheral blood with undetectable (<10-4) minimal residual disease at month 24
NCT07685717	Phase 2	Recruiting	50	Rate of treatment discontinuation
NCT07684950	Phase 2	Not yet recruiting	45	Complete Response Rate at 6 Months in Cohort 1

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.

Phase 3; n=253; evaluation: Positive. Reported fields: AE = Any-grade infection occurred in 59.9% of pts; neutropenia in 18.3% and grade ≥3 bleeding in 2.4%. Any-grade hypertension occurred in 10.7% of pts and atrial fibrillation/flutter was reported in 2.8%.

PIRTOBRUTINIB IN TREATMENT-NAÏVE PATIENTS WITH CLL/SLL: POOLED RESULTS FROM BRUIN CLL-313 AND BRUIN CLL-314

Phase 3; n=253; evaluation: Positive. Reported fields: mOS(24-month) = 97.2 % ( 91.5 - 99.1); mOS(24-month) = 97.8 % ( 93.3 - 99.3); mOS(24-month) = 97.5 % ( 94.6 - 98.9)

REAL WORLD ANALYSIS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (RRMCL) – AN ANALYSIS FROM THE EUROPEAN MANTLE CELL LYMPHOMA-REGISTRY (EMCL-R)

Not Applicable; n=208; evaluation: Positive. Reported fields: AE(grade ≥ 3) = Infections accounted for 41% and hematologic toxicities for 28% of all grade ≥3 AEs. Four AEs of grade 5 occurred, however deaths were dominantly attributable to disease progression. ; AE(grade ≥ 3) = Infections accounted for 41% and hematologic toxicities for 28% of all grade ≥3 AEs. Four AEs of grade 5 occurred, however deaths were dominantly attributable to disease progression.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pirtobrutinib addresses Refractory Small Lymphocytic Lymphoma, Chronic lymphocytic leukaemia refractory, Recurrent Chronic Lymphoid Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-03-25	Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	Approved	Financial terms not disclosed
2022-03-28	Innovent and Lilly Expand Strategic Partnership in Oncology	Approved	US$45.0M upfront
2019-01-07	Lilly Completes Acquisition of Loxo Oncology	NDA/BLA	US$8,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO